TapewireFind a company

person · Reporting owner

Muller Lorenz

Disclosed activity across 1 company

Tapewire entity
67560
SEC CIK
0001771207

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Milestone Pharmaceuticals Inc.MIST · Entity 6561Chief Commercial OfficerFebruary 02, 2026February 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Milestone Pharmaceuticals Inc.

Report date February 02, 2026 · Filed February 05, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2036-02-02Direct204,000 Reported balance After 2026-02-02 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2026-02-02 · Grant · Acquired 204,000 · Balance 204,000

F1: The exercise price on the initial filings was incorrectly stated.

F2: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price on the initial filings was incorrectly stated.

F2: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 02, 2026 Filed Feb 4, 2026 22:52 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantRestricted Stock Unit · Derivative 136,000 $0.00 $0.00
Disclosure

SEC source: 0001771207-26-000004 · form4-02042026_100201.xml · derivative · entry 2

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,000

Underlying: Common Shares · 136,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share.

F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date.

F3 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 22:52 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantEmployee Stock Option (right to buy) · Derivative 204,000 $0.00 Strike: $1.97 $0.00
Disclosure

SEC source: 0001771207-26-000004 · form4-02042026_100201.xml · derivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 204,000

Underlying: Common Shares · 204,000 shares

Expires 2036-02-02

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
February 02, 2026 Filed Feb 5, 2026 21:30 UTC Amendment Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantEmployee Stock Option (right to buy) · Derivative 204,000 $0.00 Strike: $1.96 $0.00
Disclosure

SEC source: 0001771207-26-000005 · form4a-02052026_040210.xml · derivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 204,000

Underlying: Common Shares · 204,000 shares

Expires 2036-02-02

F1 · derivative.exercise_price: The exercise price on the initial filings was incorrectly stated.

F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
January 26, 2026 Filed Jan 28, 2026 23:30 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 Exercise / conversionRestricted Stock Units · Derivative 20,100 $0.00 $0.00
Disclosure

SEC source: 0001771207-26-000002 · form4-01282026_060105.xml · derivative · entry 6

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,300

Underlying: Common Shares · 20,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one common share.

F7 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.

F7 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
January 26, 2026 Filed Jan 28, 2026 23:30 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 SaleCommon Shares 11,180 $1.93 $21,577.40
Disclosure

SEC source: 0001771207-26-000002 · form4-01282026_060105.xml · nonDerivative · entry 4

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,406

F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 26, 2026 Filed Jan 28, 2026 23:30 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 Exercise / conversionCommon Shares 20,100 Not disclosed Not disclosed
Disclosure

SEC source: 0001771207-26-000002 · form4-01282026_060105.xml · nonDerivative · entry 3

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,586

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each RSU represents a contingent right to receive one common share.

Read SEC document
December 15, 2025 Filed Jan 28, 2026 23:30 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 SaleCommon Shares 53,566 $2.32 $124,273.12
Disclosure

SEC source: 0001771207-26-000002 · form4-01282026_060105.xml · nonDerivative · entry 2

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,486

F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
December 12, 2025 Filed Jan 28, 2026 23:30 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantEmployee Stock Option (right to buy) · Derivative 100,000 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001771207-26-000002 · form4-01282026_060105.xml · derivative · entry 5

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Shares · 100,000 shares

Expires 2034-05-06

F6 · derivative.exercise_date: 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
December 12, 2025 Filed Jan 28, 2026 23:30 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantCommon Shares 100,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001771207-26-000002 · form4-01282026_060105.xml · nonDerivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,052

F1 · shares: Represents a performance stock unit ("PSU") award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil).

F2 · price: Each PSU represents a contingent right to receive one common share.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:15 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GiftCommon Shares 25,000 $0.00 $0.00
Disclosure

SEC source: 0001771207-25-000002 · form4-12112025_041204.xml · nonDerivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,052

F1 · kind: Represents a bona fide gift for no consideration to members of the Reporting Person's family outside the Reporting Person's household.

Read SEC document
July 11, 2025 Filed Jul 15, 2025 20:15 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantSeries B Common Warrants (right to buy) · Derivative 66,666 Not disclosed Strike: $1.88 Not disclosed
Disclosure

SEC source: 0001415889-25-019771 · form4-07152025_040705.xml · derivative · entry 3

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,666

Underlying: Common Shares · 66,666 shares

Expires 2030-07-11

F1 · price: The reported securities are included within 66,666 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 66,666 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

Read SEC document
July 11, 2025 Filed Jul 15, 2025 20:15 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantSeries A Common Warrants (right to buy) · Derivative 66,666 Not disclosed Strike: $1.50 Not disclosed
Disclosure

SEC source: 0001415889-25-019771 · form4-07152025_040705.xml · derivative · entry 2

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,666

Underlying: Common Shares · 66,666 shares

Expires 2026-07-11

F1 · price: The reported securities are included within 66,666 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 66,666 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

Read SEC document
July 11, 2025 Filed Jul 15, 2025 20:15 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantCommon Shares 66,666 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-019771 · form4-07152025_040705.xml · nonDerivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,052

F1 · price: The reported securities are included within 66,666 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 66,666 shares of common stock.

Read SEC document
January 27, 2025 Filed Jan 29, 2025 21:15 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantRestricted Stock Unit · Derivative 80,400 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-002268 · form4-01292025_040111.xml · derivative · entry 2

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,400

Underlying: Common Shares · 80,400 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share.

F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of Jaunary 27, 2026, Jaunary 27, 2027, Jaunary 27, 2028 and Jaunary 27, 2029, subject to the Reporting Person continuing to provide service through each such date.

F3 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of Jaunary 27, 2026, Jaunary 27, 2027, Jaunary 27, 2028 and Jaunary 27, 2029, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
January 27, 2025 Filed Jan 29, 2025 21:15 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantEmployee Stock Option (right to buy) · Derivative 120,600 $0.00 Strike: $2.02 $0.00
Disclosure

SEC source: 0001415889-25-002268 · form4-01292025_040111.xml · derivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,600

Underlying: Common Shares · 120,600 shares

Expires 2035-01-27

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on Jaunary 27, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
February 16, 2023 Filed Feb 17, 2023 21:52 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantEmployee Stock Option (right to buy) · Derivative 105,000 $0.00 Strike: $3.59 $0.00
Disclosure

SEC source: 0001209191-23-010707 · doc4.xml · derivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Shares · 105,000 shares

Expires 2033-02-16

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 16, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
March 21, 2022 Filed Mar 24, 2022 01:46 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantEmployee Stock Option Grant (right to buy) · Derivative 160,000 $0.00 Strike: $5.46 $0.00
Disclosure

SEC source: 0001209191-22-020838 · doc4.xml · derivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Shares · 160,000 shares

Expires 2032-03-21

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on March 23, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
March 24, 2021 Filed Mar 27, 2021 00:37 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantEmployee Stock Option (right to buy) · Derivative 200,000 $0.00 Strike: $6.26 $0.00
Disclosure

SEC source: 0001209191-21-023350 · doc4.xml · derivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Shares · 200,000 shares

Expires 2031-03-24

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on March 24, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
August 26, 2020 Filed Aug 28, 2020 21:00 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 5,700 $0.00 Strike: $1.54 $0.00
Disclosure

SEC source: 0001209191-20-048651 · doc4.xml · derivative · entry 2

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,754

Underlying: Common Stock · 5,700 shares

Expires 2027-10-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The original grant was for 140,100 option shares. Twenty-five percent (25%) of the shares subject to the option vested on October 11, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
August 26, 2020 Filed Aug 28, 2020 21:00 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 Exercise / conversionCommon Stock 5,700 $1.54 $8,778.00
Disclosure

SEC source: 0001209191-20-048651 · doc4.xml · nonDerivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,386

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 05, 2020 Filed Jun 8, 2020 22:59 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantEmployee Stock Option (right to buy) · Derivative 35,000 $0.00 Strike: $3.74 $0.00
Disclosure

SEC source: 0001209191-20-035110 · doc4.xml · derivative · entry 7

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Shares · 35,000 shares

Expires 2030-06-05

F3 · derivative.exercise_date: The shares subject to this option shall vest in twenty-four (24) equal monthly installments commencing on July 5, 2020, subject to the recipient continuing to provide service to the Issuer through each such date.

Read SEC document
April 03, 2020 Filed Jun 8, 2020 22:59 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 18,043 $0.00 Strike: $1.54 $0.00
Disclosure

SEC source: 0001209191-20-035110 · doc4.xml · derivative · entry 6

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,903

Underlying: Common Shares · 18,043 shares

Expires 2028-10-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The original grant was for 50,946 option shares. Twenty-five percent (25%) of the shares subject to the option shall vest on October 15, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
April 03, 2020 Filed Jun 8, 2020 22:59 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 32,528 $0.00 Strike: $1.54 $0.00
Disclosure

SEC source: 0001209191-20-035110 · doc4.xml · derivative · entry 5

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,454

Underlying: Common Shares · 32,528 shares

Expires 2027-10-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The original grant was for 140,100 option shares. Twenty-five percent (25%) of the shares subject to the option vested on October 11, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
April 03, 2020 Filed Jun 8, 2020 22:59 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 Exercise / conversionCommon Shares 18,043 $1.54 $27,786.22
Disclosure

SEC source: 0001209191-20-035110 · doc4.xml · nonDerivative · entry 3

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 03, 2020 Filed Jun 8, 2020 22:59 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 Exercise / conversionCommon Shares 32,528 $1.54 $50,093.12
Disclosure

SEC source: 0001209191-20-035110 · doc4.xml · nonDerivative · entry 2

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,643

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 23, 2020 Filed Jan 24, 2020 22:35 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 GrantEmployee Stock Option (right to buy) · Derivative 60,000 $0.00 Strike: $21.48 $0.00
Disclosure

SEC source: 0001209191-20-004895 · doc4.xml · derivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Shares · 60,000 shares

Expires 2030-01-23

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on January 23, 2021 and one forty-eighth (1/48th) of the shares subject to the option vest on each one month anniversary thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
October 01, 2019 Filed Jun 8, 2020 22:59 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 2,500 $0.00 Strike: $1.54 $0.00
Disclosure

SEC source: 0001209191-20-035110 · doc4.xml · derivative · entry 4

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,982

Underlying: Common Shares · 2,500 shares

Expires 2027-10-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The original grant was for 140,100 option shares. Twenty-five percent (25%) of the shares subject to the option vested on October 11, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Read SEC document
October 01, 2019 Filed Jun 8, 2020 22:59 UTC Milestone Pharmaceuticals Inc. MIST · Entity 6561 Exercise / conversionCommon Shares 2,500 $1.54 $3,850.00
Disclosure

SEC source: 0001209191-20-035110 · doc4.xml · nonDerivative · entry 1

Muller Lorenz · CIK 0001771207 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,115

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.